Date: 2011-02-28
Type of information: Company acquisition
Acquired company: Avogadro (France)
Acquiring company: Amatsi (France)
Amount: undisclosed
Terms: The contract drug development organizations Amatsi (Formerly CRID Pharma) and Avogadro have agreed to combine their strenghts to become the French leader in this sector. This move has been supported by Acto Capital, a direct investment company of Groupama Private Equity, and who are now the main shareholder of the Amatsi group that has been formed. The directors of Amatsi-Avogadro also remain shareholders.
Details: The new AMATSI - AVOGADRO, located at Montpellier and Toulouse in France and Cambridge in the USA, is a Contract Development and Manufacturing Organization (CDMO) specializing in drug development services. AMATSI has been supporting the pharmaceutical and biotech industries in the clinical development of their drug candidates intended to human or veterinary use for more than twenty years. With its strong team of 175 staff, AMATSI-AVOGADRO offers specialised pharmaceutical development services (galenic and analytical development, PK-ADME studies/ bioanalysis/ residues, quality control, ICH stability study and regulatory support) and clinical supplies management (manufacturing, packaging, storage and logistics).
Related: Drug development services
